Home > Rheumatology > ACR 2019 > Reproductive Issues in Rheumatic Disease > Prevention of Congenital Heart Block May Be Possible with Hydroxychloroquine

Prevention of Congenital Heart Block May Be Possible with Hydroxychloroquine

Presented By
Prof. Peter Izmirly, New York University School of Medicine, USA
Conference
ACR 2019
Trial
PATCH

Treatment with hydroxychloroquine significantly reduced the recurrence rate of congenital heart block (CHB) for children of mothers with a previous child affected [1].

CHB is one of the clinical manifestations of a neonatal lupus syndrome [2]. It is associated with a 17.5% mortality and 70% requirement of permanent pacing [3]. The disease is induced by a placental transport of maternal anti-SSA/Ro antibodies [2]. Women carrying these antibodies may have systemic lupus erythematosus, Sjögren syndrome, or other connective tissue disease, or may be completely healthy at the time of giving birth [2].
“CHB affects an estimated 2% of pregnancies among women who have anti-SSA/Ro antibodies who have never been pregnant or have never had an affected child. It appears maternal health accompanying the production of the candidate autoantibodies is not a risk factor for foetal disease, since many mothers whose foetuses develop cardiac injury are asymptomatic and ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on